ADCT — ADC Therapeutics SA
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1771910 ·
Last close
$1.26
Market Cap
$160.86M
52W High
$4.98
52W Low
$0.78
ADV30
1,793,804
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 19,248,000 | 16,899,000 | -22,778,000 | -16,565,000 | 279,379,000 | 219,107,000 | 507,584,000 |
| Mar 2026 | 20,851,000 | 17,236,000 | -25,245,000 | -32,968,000 | 291,496,000 | 231,008,000 | 507,873,000 |
| Dec 2025 | 23,058,000 | 21,359,000 | -18,123,000 | -6,409,000 | 323,150,000 | 261,338,000 | 508,984,000 |
| Sep 2025 | 16,427,000 | 15,225,000 | -30,326,000 | -40,966,000 | 289,758,000 | 234,738,000 | 527,941,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-114,550,000
Investing CF
$627,000
Financing CF
$150,091,000
CapEx
$-386,000
Dividends Paid
—
Buybacks
$-20,000
EPS Diluted TTM
$-1.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,668,909,000
Inventory
$4,776,000
Receivables
$31,045,000
ST Investments
—
EBIT TTM
$-84,387,000
Pretax Income TTM
$-136,139,000
Interest Exp TTM
$51,752,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,584,000
EBITDA
$-93,706,496
Free Cash Flow
$-68,119,872
Enterprise Value
$355,688,448
Total Cash
$219,107,008
Total Debt
$438,191,008
Shares Out
127,667,695
Trailing EPS
$-0.58
Book Value
$-1.79
ROE
—
ROA
-19.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 81,357,000 | -107,207,000 | -142,623,000 | 323,150,000 | 508,984,000 | -185,834,000 | -141,174,000 |
| Dec 2024 | 70,837,000 | -129,591,000 | -157,846,000 | 321,980,000 | 524,622,000 | -202,642,000 | -123,835,000 |
| Dec 2023 | 69,558,000 | -165,051,000 | -240,053,000 | 354,782,000 | 503,031,000 | -148,249,000 | -118,686,000 |
| Dec 2022 | 209,908,000 | -122,987,000 | -157,128,000 | 490,859,000 | 411,408,000 | 79,451,000 | -138,311,000 |
TTM Snapshot
Revenues TTM
$17,410,000
NetIncome TTM
$-36,544,000
OpCashFlow TTM
$0
Assets (Latest)
$321,980,000
Forward EPS
$-1.49
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $1.26 · call oi: 2,486 · put oi: 0
Expected Move to 2027-01-15:
±$1.60
(126.98%) —
implied range
$-0.34 –
$2.86
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | $162.34M | $3.40 | — |
| NBP | NovaBridge Biosciences | $157.28M | $1.36 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $156.41M | $1.09 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $169.80M | $9.90 | — |
| MENS | Jyong Biotech Ltd. | $146.24M | $1.97 | — |
News headlines (Yahoo Finance, 1h cache)
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-03 11:15 · Yahoo
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
2026-08-20 19:49 · Yahoo
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
2026-08-16 03:15 · Yahoo
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...
2026-08-13 23:07 · Yahoo
ADC Therapeutics Q2 Earnings Call Highlights
2026-08-13 20:04 · Yahoo
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 12:50 · Yahoo
ADC Therapeutics Announces New Employee Inducement Grant
2026-07-01 20:05 · Yahoo
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
2026-06-30 11:15 · Yahoo
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views
2026-06-27 09:08 · Yahoo
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details
2026-06-24 13:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.